TELA Bio, Inc. (NASDAQ:TELA) reported mixed results for the fourth quarter on Tuesday.
The company posted quarterly losses of 17 cents per share which beat the analyst consensus estimate of losses of 18 cents per share. The company reported quarterly sales of $20.869 million which missed the analyst consensus estimate of $21.047 million.
TELA Bio said it sees first-quarter sales of $18.500 million versus market estimates of $21.277 million.
“We closed 2025 with our strongest quarterly revenue on record, delivering $20.9 million and 18% growth over Q4 2024 while holding operating expenses essentially flat for the year, demonstrating the operating leverage we expect to continue to see in the years ahead,” said Antony Koblish, Co-Founder and Chief Executive Officer of TELA Bio. “Over the last six months we strengthened our leadership and upgraded the …